Filtered By:
Specialty: Hematology
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 677 results found since Jan 2013.

A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits
Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin has limitations that have motivated development of several novel oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban. Clinical trials demonstrate that the NOACs offer efficacy and safety that are equivalent to, or better than, those of warfarin for reducing the risk of stroke in patients with nonvalvular AF. This review examines stroke risk reduction in patients with AF from the perspe...
Source: Thrombosis Journal - August 21, 2015 Category: Hematology Authors: Alpesh AminSteven Deitelzweig Source Type: research

Mean platelet volume is related with ischemic stroke in patients with sinus rhythm
Stroke is the leading cause of disability worldwide. It is known that atrial fibrillation and left atrial enlargement contribute ischemic stroke, and mean platelet volume (MPV) increases in patients with ischemic stroke and atrial fibrillation. We aimed to determine whether higher MPV is associated with ischemic stroke in patients with sinus rhythm. We evaluated 74 patients in sinus rhythm and with ischemic stroke (Group 1) and 90 age-matched and sex-matched healthy individuals as control group (Group 2). After physical and echocardiographic examination, 24–48 h Holter monitoring and complete blood counts were studied....
Source: Blood Coagulation and Fibrinolysis - July 1, 2016 Category: Hematology Tags: Original Articles Source Type: research

The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis.
Authors: Marszalek J, Mehrsefat S, Chi G Abstract Data from recent randomized controlled trials indicate that the incidence of stroke among acutely ill medical patients is unexpectedly high and approximates 1% at 90 days. Preliminary data suggest that betrixaban may reduce ischemic stroke in patients without atrial fibrillation. There is an unmet demand for stroke risk stratification schemes targeting hospitalized medical patients. The prognostic value of biomarkers such as natriuretic peptides and D-dimer in predicting short-term stroke remains uncertain. Future research should focus on identifying the high-risk s...
Source: Expert Review of Hematology - June 16, 2017 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Secondary stroke prevention in patients with patent foramen ovale
Purpose of review Although a patent foramen ovale (PFO) is an established risk factor for cryptogenic ischemic stroke, strategies for secondary prevention remain controversial. Increasing evidence over the past decade from well designed clinical trials supports transcatheter PFO closure for selected patients whose stroke was likely attributable to the PFO. However, patient selection using imaging findings, clinical scoring systems, and in some cases, thrombophilia testing, is crucial for determining patients most likely to benefit from closure, anticoagulation, or antiplatelet therapy. Recent findings Recent stu...
Source: Current Opinion in Hematology - August 6, 2021 Category: Hematology Tags: HEMOSTASIS AND THROMBOSIS: Edited by Paul F. Bray Source Type: research

Atrial Fibrillation Detected by Single Timepoint Handheld ECG Screening and the Risk of Ischemic Stroke
CONCLUSION: The prognosis of single timepoint ECG screen-detected AF is not benign. The risk of stroke is high enough to warrant OAC use, and reduced by OAC.PMID:34399432 | DOI:10.1055/a-1588-8867
Source: Thrombosis and Haemostasis - August 16, 2021 Category: Hematology Authors: Wen Sun Ben Freedman Carlos Martinez Christopher Wallenhorst Bryan Yan Source Type: research

JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients
The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis consisted of 5,220 patients who were tested for JAK2V617F and 1,047,258 people matched in age from health care insurance provider, taking into account age, sex, hypertension, diabetes, atrial fibrillation. Compared with noncarriers, mutation carriers were older, less likely to be current or past smokers and had lower body mass index. There was no significant difference between the group...
Source: Thrombosis and Haemostasis - March 15, 2022 Category: Hematology Authors: Tamar Shapira Cohen Gabriel Chodick David M Steinberg Ehud Grossman Mordechai Shohat Ophira Salomon Source Type: research

Stroke and myocardial infarction in patients with abdominal aortic aneurysms and new-onset atrial fibrillation
Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and myocardial infarction.PMID:36626930 | DOI:10.1055/a-2009-8954
Source: Thrombosis and Haemostasis - January 10, 2023 Category: Hematology Authors: Chalotte Winther Winther Nicolajsen Peter Br ønnum Nielsen Martin Jensen Nikolaj Eldrup Torben Bjerregaard Larsen Gregory Yh Lip Samuel Z Goldhaber Mette S øgaard Source Type: research

Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants
New orally administered anticoagulants will simplify stroke-prevention strategies in patients with atrial fibrillation (AF). Novel anticoagulants, such as dabigatran etexilate, a direct thrombin inhibitor, and rivaroxaban, a direct factor Xa inhibitor, have been approved by the US Food and Drug Administration for the prevention of stroke and systemic embolism in patients with nonvalvular AF. In addition, the factor Xa inhibitor apixaban has been reported to be as effective as warfarin in a large, randomized clinical trial, and the efficacy of edoxaban is being assessed in a phase III warfarin comparison trial. This review ...
Source: Clinical and Applied Thrombosis/Hemostasis - June 3, 2013 Category: Hematology Authors: Haft, J. I. Tags: Review Source Type: research

Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States
Abstract This retrospective analysis investigated the impact of baseline clinical characteristics, including atrial fibrillation (AF), on hospital discharge status (to home or continuing care), mortality, length of hospital stay, and treatment costs in patients hospitalized for stroke. The analysis included adult patients hospitalized with a primary diagnosis of ischemic or hemorrhagic stroke between January 2006 and June 2011 from the premier alliance database, a large nationally representative database of inpatient health records. Patients included in the analysis were categorized as with or without AF, based on...
Source: Journal of Thrombosis and Thrombolysis - November 5, 2014 Category: Hematology Source Type: research

Usefulness of mean platelet volume for predicting stroke risk in paroxysmal atrial fibrillation patients
Atrial fibrillation is the most common sustained arrhythmia in clinical practice. It is important to specify patients with a high risk of thromboembolus due to elevated procoagulant and prothrombotic state. The aim of this study is to assess the relation of stroke/transient ischaemic attack (TIA) with mean platelet volume (MPV), which is an indicator of platelet activation in patients with paroxysmal atrial fibrillation (PAF). Patients with PAF were enrolled in this study during years of 2012–2014. Patients were divided into two groups according to the presence or absence of stroke/TIA. Demographic data were registered a...
Source: Blood Coagulation and Fibrinolysis - August 5, 2015 Category: Hematology Tags: Original Articles Source Type: research

The prediction of postoperative stroke or death in patients with preoperative atrial fibrillation undergoing non‐cardiac surgery: a VISION sub‐study
ConclusionsIn AF patients, the 3 thromboembolic risk scores performed similarly to the RCRI in predicting death within 30 days and the CHADS2 score was the best predictor of postoperative stroke/death regardless of type of surgery.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - August 13, 2015 Category: Hematology Authors: Finlay A. McAlister, Michael Jacka, Michelle Graham, Erik Youngson, George Cembrowski, Sean M. Bagshaw, Neesh Pannu, Derek R. Townsend, Sadeesh Srinathan, Pablo Alonso‐Coello, P J Devereaux Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Stroke in atrial fibrillation and improving the identification of 'high risk' patients: the crossroads of immunity and thrombosis.
This article is protected by copyright. All rights reserved. PMID: 26303061 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 25, 2015 Category: Hematology Authors: Shantsila E, Lip GY Tags: J Thromb Haemost Source Type: research